Eli Lilly said combining Taltz and Zepbound improved arthritis symptoms and drove meaningful weight loss, outperforming Taltz ...

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.

Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis ...

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese ...

Headache wasn’t reported as a side effect in Zepbound’s studies. But, it may be a symptom of some of Zepbound’s side effects. More common side effects of Zepbound are digestive side effects, such as ...

Arrowhead’s experimental therapy helped patients on Lilly’s Zepbound lose more weight and visceral fat—but cost and ...

These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.

Lymphedema after head and neck cancer is considerably more common than previously assumed and can persist long after cancer treatment has finished. Researchers at Lund University in Sweden have ...

The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity ...

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug candidate, teeing the drugmaker up to target people taking Novo Nordisk’s ...